EP1663221A4 - Ophthalmische zusammensetzungen zur behandlung der okularen hypertonie - Google Patents

Ophthalmische zusammensetzungen zur behandlung der okularen hypertonie

Info

Publication number
EP1663221A4
EP1663221A4 EP04782774A EP04782774A EP1663221A4 EP 1663221 A4 EP1663221 A4 EP 1663221A4 EP 04782774 A EP04782774 A EP 04782774A EP 04782774 A EP04782774 A EP 04782774A EP 1663221 A4 EP1663221 A4 EP 1663221A4
Authority
EP
European Patent Office
Prior art keywords
ocular hypertension
ophthalmic compositions
treating ocular
treating
ophthalmic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04782774A
Other languages
English (en)
French (fr)
Other versions
EP1663221A1 (de
Inventor
Meng Hsin Chen
James B Doherty
Luping Liu
Swaminathan Natarajan
Robert M Tynebor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP1663221A1 publication Critical patent/EP1663221A1/de
Publication of EP1663221A4 publication Critical patent/EP1663221A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP04782774A 2003-09-04 2004-08-31 Ophthalmische zusammensetzungen zur behandlung der okularen hypertonie Withdrawn EP1663221A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50009003P 2003-09-04 2003-09-04
PCT/US2004/028351 WO2005025568A1 (en) 2003-09-04 2004-08-31 Ophthalmic compositions for treating ocular hypertension

Publications (2)

Publication Number Publication Date
EP1663221A1 EP1663221A1 (de) 2006-06-07
EP1663221A4 true EP1663221A4 (de) 2009-04-22

Family

ID=34312180

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04782774A Withdrawn EP1663221A4 (de) 2003-09-04 2004-08-31 Ophthalmische zusammensetzungen zur behandlung der okularen hypertonie

Country Status (7)

Country Link
US (1) US7494983B2 (de)
EP (1) EP1663221A4 (de)
JP (1) JP2007504236A (de)
CN (1) CN1842335A (de)
AU (1) AU2004271978B2 (de)
CA (1) CA2537430A1 (de)
WO (1) WO2005025568A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1581503A4 (de) * 2002-11-08 2007-07-25 Merck & Co Inc Ophthalmische zusammensetzungen zur behandlung der okularen hypertonie
AU2004272546B2 (en) * 2003-09-04 2007-10-18 Merck Sharp & Dohme Corp. Ophthalmic compositions for treating ocular hypertension
US8299079B2 (en) 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
WO2010135731A1 (en) * 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2534580A1 (fr) * 1982-10-13 1984-04-20 Synthelabo Derives de phenyl-1 piperidino-2 propanol, leur preparation, et medicaments qui les contiennent
US5151444B1 (en) * 1987-09-18 1999-07-06 R Tech Ueno Ltd Ocular hypotensive agents
AU3693789A (en) 1988-05-10 1989-11-29 Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktieselskab) New ophthalmic preparation for treating glaucoma
ES2317964T5 (es) * 1988-09-06 2015-02-20 Pfizer Health Ab Derivado de prostaglandina-F2alfa para el tratamiento de glaucoma o hipertensión ocular
US5296504A (en) * 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5352708A (en) * 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5922773A (en) 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
CA2164733A1 (en) 1993-06-08 1994-12-22 Nino Sorgente Methods and compositions for lowering intraocular pressure
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US5573758A (en) 1995-04-28 1996-11-12 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
US5925342A (en) * 1996-11-13 1999-07-20 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
EP1114816A4 (de) 1998-09-14 2002-09-04 Ono Pharmaceutical Co $g(v)-SUBSTITUIERTE PHENYL-PROSTAGLANDIN-E-DERIVATE UND SIE ALS AKTIVEN BESTANDTEIL ENTHALTENDE MEDIKAMENTE
TWI262914B (en) * 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
PE20010306A1 (es) * 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
EA005293B1 (ru) 1999-12-22 2004-12-30 Пфайзер Продактс Инк. Производные пирролидин-2-она и их применение при лечении остеопороза
PL358481A1 (en) 2000-03-17 2004-08-09 Alcon Inc. 6-hydroxy-indazole derivatives for treating glaucoma
WO2001070701A1 (en) * 2000-03-17 2001-09-27 Alcon, Inc. 5-hydroxy indazole derivatives for treating glaucoma
WO2001072268A1 (en) 2000-03-31 2001-10-04 Toray Industries, Inc. Hair growth or hair formation controlling agents
WO2002024647A1 (en) 2000-09-21 2002-03-28 Ono Pharmaceutical Co., Ltd. Ep4 receptor agonists containing 8-azaprostaglandin derivatives as the active ingredient
EA200300379A1 (ru) 2000-11-27 2003-08-28 Пфайзер Продактс Инк. Селективные агонисты рецептора ep4 в лечении остеопороза
DK1392292T3 (da) * 2001-06-01 2006-05-29 Alcon Inc Pyranoindazoler og deres anvendelse til behandling af glaukom
EP1581503A4 (de) * 2002-11-08 2007-07-25 Merck & Co Inc Ophthalmische zusammensetzungen zur behandlung der okularen hypertonie
US7053085B2 (en) 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
EP1479675A1 (de) * 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Indazolderivate als Faktor Xa-Inhibitoren

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *

Also Published As

Publication number Publication date
AU2004271978A1 (en) 2005-03-24
EP1663221A1 (de) 2006-06-07
CN1842335A (zh) 2006-10-04
US7494983B2 (en) 2009-02-24
CA2537430A1 (en) 2005-03-24
WO2005025568A1 (en) 2005-03-24
JP2007504236A (ja) 2007-03-01
US20070027188A1 (en) 2007-02-01
AU2004271978B2 (en) 2009-02-05

Similar Documents

Publication Publication Date Title
EP1646614A4 (de) Ophthalmische zusammensetzungen zur behandlung der okularen hypertonie
EP1666027A4 (de) Ophthalmische zusammensetzung für kontaktlinse
EP1581503A4 (de) Ophthalmische zusammensetzungen zur behandlung der okularen hypertonie
EP1664011A4 (de) Ophthalmische zusammensetzungen zur behandlung der okularen hypertonie
EP1515722A4 (de) Ophthalmische zusammensetzungen zur behandlung der okularen hypertonie
BRPI0317545A2 (pt) "composições de poli-hema de baixa polidispersão"
AU2002305278A1 (en) Bifurcatable trabecular shunt for glaucoma treatment
IS7215A (is) Aðferðir til að meðhöndla nýæðarsjúkdóma í augum
DZ3347A1 (fr) Dérivés d'arylméthylamine pour leur utilisation comme inhibiteurs de la tryptase
EP1583750A4 (de) Macrocyclische beta-sekretaseinhibitorenzur behandlung von alzheimer-krankheit
EP1534074A4 (de) Kombinationstherapie zur behandlung von fettleibigkeit
GB2402674B (en) Compositions and methods for the treatment of glaucoma or ocular hypertension
PL377172A1 (pl) Kompozycje do oczu do leczenia nadciśnienia śródgałkowego
FR2860654B1 (fr) Bougie d'allumage pour temperatures elevees
EP1515721A4 (de) Ophthalmische zusammensetzungen zur behandlung der okularen hypertonie
NO20020319D0 (no) Oftalmisk sammensetning
FR2879914B1 (fr) Ecarteur-retenteur d'intestins pour chirurgie coelioscopique
EP1771170A4 (de) Ophthalmische zusammensetzungen zur behandlung der okularen hypertonie
EP1558238A4 (de) Beta-hydroxyphenylaldylamine und ihre verwendung zur behandlung von glaukom
EP1663221A4 (de) Ophthalmische zusammensetzungen zur behandlung der okularen hypertonie
EP1660685A4 (de) Antisense-hemmung der laminin-8-expression zur hemmung von gliomen im menschen
EP1802300A4 (de) Ophthalmische zusammensetzungen zur behandlung von augenhochdruck
EP1610776A4 (de) Ophthalmische zusammensetzungen zur behandlung der okularen hypertonie
ZA200302911B (en) Method and composition for treatment of ocular hypertension and glaucoma.
EP1410795A4 (de) Mittel zur behandlung allergischer augenerkrankungen

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060404

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: LT LV

RAX Requested extension states of the european patent have changed

Extension state: LV

Payment date: 20060404

Extension state: LT

Payment date: 20060404

A4 Supplementary search report drawn up and despatched

Effective date: 20090324

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20100112